Relapse is the most common cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL) and is often difficult to predict. To explore the prognostic impact of recurrent DNA copy number abnormalities on relapse, we performed high-resolution genomic profiling of 34 paired diagnosis and relapse ALL samples. Recurrent lesions detected at diagnosis, including PAX5, CDKN2A and EBF1, were frequently absent at relapse, indicating that they represent secondary events that may be absent in the relapse-prone therapy-resistant progenitor cell. In contrast, deletions and nonsense mutations in IKZF1 (IKAROS) were highly enriched and consistently preserved at the time of relapse. A targeted copy number screen in an unselected cohort of 131 precursor B-ALL cases, enrolled in the dexamethasone-based Dutch Childhood Oncology Group treatment protocol ALL9, revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Separate analysis of ALL9-treatment subgroups revealed that non-high-risk (NHR) patients with IKZF1 deletions exhibited a B12-fold higher relative relapse rate than those without IKZF1 deletions. Consequently, IKZF1 deletion status allowed the prospective identification of 53% of the relapse-prone NHR-classified patients within this subgroup and, therefore, serves as one of the strongest predictors of relapse at the time of diagnosis with high potential for future risk stratification.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Despite remarkable improvements in the treatment of this malignancy during the last 30 years, still 25% of the children relapse with a survival rate of o30% and their prognosis remains poor. 1, 2 In the past, it has been shown that specific chromosome anomalies are of considerable prognostic importance and, as such, they are routinely used in the course of clinical decision making. 1, 2 For example, t(9;22)(q34;q11)-associated BCR-ABL1 gene fusions and 11q23-associated MLL gene rearrangements relate to poor prognoses with high relapse rates. However, as the frequencies of these lesions are low, they account for only a minority of the relapses in ALL.
The recent application of high-resolution genomic profiling has significantly contributed to our understanding of the genetic defects underlying ALL development. For example, others have used single-nucleotide polymorphism-based genomic profiling to detect recurrent DNA copy number anomalies and acquired homozygosity in pediatric precursor B-ALL. [3] [4] [5] As a result, several novel focal deletions targeting only (parts of) single genes were identified, including the B-cell differentiation regulators PAX5, EBF1, IKZF1 (IKAROS) and E2-2 (TCF4), the cell cycle regulators CDKN2A and RB1, and the anti-apoptotic factor BTG1. Relapses in ALL are thought to result from the outgrowth of therapy-resistant residual leukemic cells, as the majority of leukemic cells in relapses represent (sub-)clones already present at diagnosis. [6] [7] [8] [9] [10] Several studies have focused on the genetic basis of relapse in pediatric ALL by comparing the genomic profiles of paired diagnosis and relapse samples. These comparisons revealed that relapse samples are genomically distinct from the predominant clone at diagnosis, and that relapsing cells commonly seem to be derived from early progenitors. [10] [11] [12] Furthermore, in each of these studies several genes were identified that were more frequently deleted in diagnosis samples from patients showing relapse as compared with those from relapse-free patients, including CDKN2A, ETV6, IKZF1 and EBF1. Some of the variations observed among different studies seem to reflect relatively small cohort sizes or differences in treatment protocols used. A comprehensive analysis of high-risk (HR) precursor B-ALL revealed that deletions or pathogenic sequence mutations in the IKZF1 gene are strongly associated with an overall poor outcome and are almost obligatory present in BCR-ABL1-positive cases. [13] [14] [15] [16] An additional significant similarity between expression signatures in HR BCR-ABL1-positive and -negative ALLs has suggested that genetic alterations in IKZF1 and/or other critical developmental genes may affect the transcriptome in both of these HR subgroups. 14, 17 Here, we compared the genomic profiles of 34 paired diagnosis and relapse precursor B-ALL samples, which allowed us to establish that IKZF1 abnormalities predominate in the samples showing relapse. As this effect is likely to be therapy-related, we analyzed an unselected cohort of 131 diagnosis samples from precursor B-ALL patients enrolled in the dexamethasone-based Dutch Childhood Oncology Group (DCOG) ALL9 treatment protocol. 18 Together, our results indicate that the IKZF1 deletion status serves as an extremely powerful prognostic marker at the time of diagnosis.
Materials and methods

Patient material and DNA isolation
All patients (age 1-18 years) included in this study were registered by the DCOG with informed consent. Paired diagnosis and relapse samples from 34 patients were obtained from the DCOG, and were treated according to one of the three recent treatment protocols used in the Netherlands (ALL7, ALL8 or ALL9). From 13 cases, additional complete remission material was available. The patient characteristics are listed in Supplementary Tables 1 and 2 . To establish the prognostic value of IKZF1 deletions, we used an unselected group of 131 uniformly treated patients diagnosed with precursor B-cell ALL between 1 January 1997 and 1 January 2000 (Supplementary Table 3) , which is a representative subset of the patients included in the dexamethasone-based DCOG ALL9 protocol (Supplementary Table 4 ). 18 Within this cohort, 102 patients were stratified into the non-high-risk (NHR) treatment group and 29 patients in the HR treatment group. In total, there were 24 relapses, of which 17 were stratified in the NHR treatment group. The diagnosis of all ALL samples was independently confirmed by the DCOG and, after Ficoll gradient separation, mononuclear cells were stored in liquid nitrogen. Genomic DNA was extracted and purified from mononuclear cells acquired at diagnosis, relapse and, if available, complete remission using standard procedures.
Array comparative genomic hybridization and data analysis
Leukemic and remission DNA samples were hybridized on Affymetrix Human GeneChip Mapping 250K NSP arrays as previously described. 3 Data were analyzed using the copy number abnormalities (CNAs) G2.0 software package 19 and CNAs were detected through an implemented Hidden Markov algorithm as well as by visual inspection. In the latter case, a minimum of eight probes (duplication) or five probes (deletion) was used as a cutoff. 20 All copy number lesions detected in diagnosis and/or relapse samples, which were also found to be present in the matched complete remission samples and/or in private or public databases of normal variation, were excluded from further analysis. Breakpoint positions of focal IKZF1 deletions and a number of additional acquired lesions in relapse samples were determined in cases 6, 9, 12, 18, 26, 27 and 34 by array comparative genomic hybridization using custom-made 384K tiling oligo arrays (Roche NimbleGen Inc, Madison, WI, USA) with a local density of 1 oligo per 30 bp, according to the manufacturer's instructions. Shortly, 500 ng of genomic DNA was sonicated to 500-2000 bp fragments, labeled with Cy3 using random-primed labeling method and hybridized overnight at 42 1C against Cy5-labeled reference DNA using a MAUI hybridization system (Biomicro Systems, Salt Lake City, UT, USA). After washing, the arrays were scanned using an Axon Genepix 4200AL microarray scanner (Molecular Devices, Sunnyvale, CA, USA). Data analyses were carried out using the NimbleScan 2.3 software package (Roche NimbleGen Inc).
Sequence analysis
Sequencing of the IKZF1 gene was performed on PCR-amplified exons using flanking intron-based primers (listed in Supplementary Table 5 ). The samples were sequenced using an ABI 3730 DNA analyzer and analyzed using the ABI Basecaller program (Applied Biosystems, Foster City, CA, USA).
Multiplex ligation-dependent probe amplification
Targeted copy number screening of the IKZF1 gene in the validation cohort was performed by multiplex ligation-dependent probe amplification (MLPA). 21 Synthetic MLPA primers were designed using the MeltIngeny program, according to the manufacturer's instructions (MRC-Holland, Amsterdam, the Netherlands). MLPA analyses were carried out using a SALSA MLPA reaction mixture (MRC-Holland), containing 0.5 nM of each primer and healthy controls as a reference (for primer sequences see Supplementary Table 5 ). Nine probes located within the IKZF1 gene were combined in one MLPA assay along with four standard control probes in three different genes, that is, VIRP2, MRPL41 and KIAA0056 (Supplementary Figure 1) . A total of 200 ng of genomic DNA was used in each MLPA reaction. Probe mix and hybridization buffer (MRC-Holland) were added in equal amounts to the genomic DNA followed by heat denaturation and overnight hybridization of the probes at 60 1C. Subsequently, ligation was performed and the ligation products were amplified by PCR using either a 6-FAM fluorophore-labeled primer set (MRC-Holland). The amplification products were quantified and identified by capillary electrophoresis on an ABI 3730 DNA analyzer (Applied Biosystems). Normalization of the data was carried out by dividing the peak area of each probe by the average peak area of the control probes. This normalized peak pattern was divided by the average peak pattern of all the samples in the same experiment.
The resulting values were B1 for every wild-type peak, 0.5 for heterozygous deletions and 1.5 for heterozygous duplications.
PCR-based detection of immunoglobulin (Ig)/T-cell receptor (TCR) gene rearrangements
Clonal Ig/TCR gene rearrangements were identified using heteroduplex PCR analysis and sequencing as previously described. [22] [23] [24] [25] [26] To compare clonal gene rearrangements between diagnosis and relapse samples, a strategy based on comparative heteroduplex PCR analysis and direct fluorescent sequencing was applied. 27 Ig/TCR gene rearrangements were considered stable if all the Ig/TCR gene rearrangements detected at diagnosis were preserved at relapse, mostly stable if the majority of the rearrangements was preserved, partially stable if B50% of the rearrangements were preserved and instable if most or all the rearrangements were absent at relapse.
Statistical analyses
The comparison of CNAs between paired diagnosis and relapse samples was carried out using Student's t-test. Patient characteristics in the unselected precursor-B ALL cohort were compared using crosstabs in conjunction with a standard Pearson w 2 -test. Survival curves were generated using the standard Kaplan-Meier method and equality of survival distribution was tested using logrank testing. The prognostic values of IKZF1 deletions on the relapse-free survival (RFS, defined as the time from diagnosis until the occurrence of recurrent disease) or the overall survival (OS, defined as the time between diagnosis and death by any cause) were calculated using uni-and multivariate (with stepwise removal of nonsignificant factors) Cox regression analyses. Statistical analyses were carried out using the SPSS statistical package (IBM, Chicago, IL, USA; release 16.0.2, April 2008) and two-sided P-values below 0.05 were considered to be statistically significant.
Results
Genomic alterations in relapsing precursor B-ALL
To explore whether recurrent CNAs in crucial genes associate with relapse in pediatric precursor B-ALL, we analyzed 34 paired diagnosis and relapse samples from children diagnosed with precursor B-ALL. The time between diagnosis and relapse varied from 6 months to 9 years. In four cases, a second relapse sample was included (Supplementary Table 1 ). From these 34 cases, seven (20%) carried BCR-ABL1 gene fusions or MLL rearrangements, indicative of a high relapse risk (Supplementary  Table 2 ). On average, we found approximately 8 and 9.6 subchromosomal lesions per diagnosis and relapse samples, respectively (Supplementary Figure 2 and Supplementary Table  6 ), which is twice the amount detected in our previously reported unselected group of diagnosis precursor B-ALL samples (P ¼ 0.044). 3 The number of lesions seemed to be slightly lower compared with what has been previously reported, 10 ,11 which may be due to the higher density arrays in these studies. Furthermore, no significant increase in the number of copy number abnormalities between diagnosis and relapse samples was found.
Relapse clones originate from early progenitors
As leukemic clones detected during ALL relapse are thought to arise from therapy-resistant (sub-)clones present at the time of diagnosis, we compared the genomic anomalies detected in diagnosis and relapse samples for each patient (Supplementary Figure 2) . Overall, 75% of the CNAs detected in the diagnosis samples were also present in the relapse samples. In only six cases we did not detect any differences between these two samples. In two of the latter cases, however, additional genomic lesions were detected in a second relapse sample (Supplementary Table 6 ). In the remaining 28 cases (82%) we found newly acquired CNAs (15%), CNAs that had disappeared (12%), or a combination of both (56%) in the relapse samples as compared with the diagnosis samples. All the four second relapse samples showed differences in CNAs compared with the earlier diagnosis and relapse samples.
Clonal rearrangements in the Ig and TCR genes provide additional information on the relation between diagnosis and relapse samples. 6, 19, 21 These loci could be analyzed at the molecular level in 29 cases (Supplementary Table 6 ). By doing so, only three cases were categorized as stable (no changes in Ig/TCR gene rearrangements), of which two contained genomic lesions at diagnosis that disappeared at relapse (Supplementary Table 6 ). In reverse, four cases did not show any differences in CNAs between the diagnosis and relapse samples, whereas changes in Ig/TCR gene rearrangements were present, indicating a subclonal origin of the relapse samples. Taken together, we conclude that the majority of the relapse clones shows genomic abnormalities different from those predominating at diagnosis. The observation that most cases show CNAs at diagnosis that do not reemerge at relapse clearly indicates that relapse clones commonly evolve from early (progenitor) cells, which are distinct from the major blast population at diagnosis.
Inactivation of IKZF1 is common in relapse-prone ALL
On the basis of the above notion, we next set out to assess whether specific CNAs in diagnosis ALL samples associate with progression to relapse. Many of the genes affected by CNAs in the diagnosis samples were also found to be recurrently affected in unselected cohorts of precursor B-cell ALLs, including ETV6, RUNX1 and the B-cell differentiation genes PAX5, IKZF1, EBF, E2-2 (TCF4) and RAG1/RAG2. 8, 9 The two most frequently occurring lesions in the relapse cohort were deletions of CDKN2A (n ¼ 15) and IKZF1 (n ¼ 13), both of which were significantly more common than in a previously analyzed unselected childhood ALL cohort 8 ( Table 1 ). The lesions affecting CDKN2A, PAX5, EBF and ETV6 were not always preserved in the relapse clone or, in reverse, occurred in the relapse clone as a novel lesion, indicating that these abnormalities may be relevant for leukemia progression but not for therapy resistance. In contrast, all IKZF1 lesions detected at diagnosis were preserved in the relapse clones. An additional IKZF1 deletion was found in one of the remaining relapse clones that was not detected at diagnosis (case 18). These findings support an association between the presence of IKZF1 lesions and the development of relapse.
To confirm and fine-map the focal IKZF1 deletions, we analyzed DNA from six cases using custom-made tiling Figure 3) . Three cases harbored intragenic deletions encompassing the DNA binding domainencoding exons 4-6. Such deletions may result in the expression of dominant-negative IKZF1 isoforms Ik6 (case 9) and Ik10 (cases 12 and 26), a phenomenon that was also previously reported in BCR-ABL1 positive ALLs. 11 Nevertheless, the majority of the deletions resulted in monoallelic loss of IKZF1 gene function. Sequencing of the entire gene in all diagnosis and relapse samples revealed two additional frameshift mutations, one in a diagnosis sample that also carried a deletion (case 6) and one single-nucleotide insertion leading to a premature stop in the relapse sample of an additional case (case 1). Together, these observations suggest that monoallelic IKZF1 gene defects, particularly copy number deletions, are common in relapseprone ALLs.
Deletion of IKZF1 predicts relapse and treatment outcome
To establish the significance of IKZF1 deletions in disease outcome, we decided to assess an independent and unselected cohort of 131 diagnosis samples from uniformly treated precursor B-cell ALL patients, diagnosed between 1997 and 2000, of which 24 (18%) developed a relapse. All patients were enrolled in the DCOG ALL9 protocol. To enable highthroughput screening of IKZF1 copy number anomalies in these samples, we developed a locus-specific MLPA assay, which allowed us to efficiently detect all the deletions initially identified by array comparative genomic hybridization in the discovery cohort (Supplementary Figure 1) . In the unselected cohort, IKZF1 deletions were detected in 50% of the patients with relapse compared with 5.6% of the patients without relapse (Po0.001, Supplementary Tables 3 and 7 ), again showing a strong association with relapse incidence. Sequencing of the gene in the remaining relapses (13 cases) revealed no additional point mutations, confirming the relative infrequency of this type of mutations. The 8-year relapse-free survival rate was 89% for patients with wild-type IKZF1 and 39% for patients with IKZF1 deletions at diagnosis (Po0.001, Figure 1a) . The overall survival rate after 8 years was 91 and 56% for IKZF1 wild-type and IKZF1 deletion cases, respectively (Po0.001, Figure 1b) . Univariate Cox regression analysis revealed that the IKZF1 deletion status at diagnosis serves as a very strong predictor for both relapse and overall survival (relative risks 9.03 and 5.71, respectively; Po0.001 for both comparisons; Supplementary Table 8) . Also in a multivariate model, the presence of IKZF1 deletions remained the strongest predictive factor for relapse-free and overall survival (relative risk 10.23 and 8.24, respectively; Po0.001; Table 3 ), thereby surpassing the previously identified prognostic factors in the DCOG ALL9 study, including the presence of BCR-ABL1 gene fusions, DNA index, age and white blood cell count. 18 As the incidences of relapse and overall survival will depend on the treatment regimens applied, we also analyzed the predictive value of IKZF1 deletion status in the two DCOG ALL9 treatment groups separately. In both the NHR and HR groups, the presence of IKZF1 deletions clearly associated with relapsefree and overall survival (Figures 1c-f) , although the number of patients in the HR group was small and the significance was lost when BCR-ABL1-positive cases were removed from the analysis cohort (Supplementary Figure 4) . In the much larger NHR group (n ¼ 102), in which 470% of the relapses occurred in this cohort, IKZF1 deletion status again served as a strong predictive factor for relapse and poor overall survival (Supplementary Table 9) , showing a nearly 12-fold higher relative risk of relapse for deletion carriers.
Discussion
Relapse is the major cause of treatment failure in children with ALL and, in most cases, is hard to predict at the time of IKZF1 deletions and prognosis in acute lymphoblastic leukemia RP Kuiper et al diagnosis. We analyzed 34 paired diagnosis and relapse samples from children with precursor B-ALL using high-resolution genome-wide copy number profiling. We found that most of the genomic lesions detected at diagnosis were preserved at the time of relapse, indicating that both leukemic outgrowths are clonal in origin (Supplementary Figure 5) . In addition, we observed that majority of the samples showed subtle differences between diagnosis and relapse, frequently involving lesions detected at the time of diagnosis that were absent at the time of relapse. In reverse, we found diagnosis and relapse samples that carried alternative lesions affecting the same gene(s), including CDKN2A and PAX5, suggesting that these lesions represent secondary events related to ALL development. Together, these data underscore previous observations indicating that leukemic blasts detected at diagnosis and relapse frequently represent different subclones derived from a common progenitor cell. 9, 10 To explore the prognostic impact of recurrent genomic abnormalities on relapse in ALL, a detailed comparison was made between diagnosis samples of patients with and without relapse. On average, relapsing ALLs harbored twice as many genomic abnormalities at diagnosis as compared with nonrelapsing ALLs, indicating that they are genomically more complex. However, the most striking finding was that deletions or mutations in IKZF1 were highly enriched in relapse-prone diagnosis samples. In contrast to, for instance, CDKN2A lesions, IKZF1 lesions were found to be preserved at relapse in all paired samples. Therefore, our data indicate that IKZF1 lesions represent early leukemogenic events associated with a high relapse rate. This association was confirmed using an unselected patient cohort subjected to a single treatment protocol, DCOG ALL9. 18 Targeted copy number screening revealed a strong enrichment of IKZF1 deletions in diagnosis samples of patients with relapse compared with those without relapse and also established the prognostic power of IKZF1 relapse prediction at diagnosis. These data are consistent with earlier studies of patients enrolled in other treatment protocols. 14, 16 Furthermore, the analysis of an unselected cohort of patients in our study revealed that IKZF1 deletion status acts as an independent risk factor and surpasses other risk factors such as BCR-ABL1 rearrangements, age and white blood cell count at diagnosis. The power of IKZF1 deletion status as an independent prognostic factor is also illustrated by the fact that both in the NHR as well as in the HR treatment group of the DCOG ALL9 study, the identification of IKZF1 deletions clearly enabled a distinction between two risk groups with different clinical outcomes. Deletions in IKZF1 were encountered in a considerable fraction of the HR precursor B-ALL cases. Previous studies have indicated that IKZF1 mutations occur frequently in BCR-ABL1-positive leukemias, but may also occur in other poor outcome ALL subgroups. [14] [15] [16] [17] Recently, it was shown that many of these cases are characterized by mutations in tyrosine kinase genes such as JAK2. 28 The high recurrence of IKZF1 lesions as compared with other HR cytogenetic abnormalities explains the better prognostic power of this abnormality at diagnosis.
Results of the DCOG ALL9 treatment protocol, which turned out to be very successful, have recently been published. 18 This moderately intensive treatment protocol reached a 5-year event-free survival rate of 81% and an overall survival rate of 86%, with significantly reduced long-term side effects in these patients. In the low-risk treatment group of this protocol, which encompassed 78% of the precursor B-cell ALL patients, the 5-year event-free survival rate was even higher (84%). The majority of relapses, however, were encountered in this low-risk group, urging a need for additional prognostic markers for risk stratification. Importantly, our data now show that of the 17 cases with a relapse in the NHR group, 9 (53%) carried an IKZF1 deletion at diagnosis. On the other hand, only four relapse-free patients in the NHR group (5%) were IKZF1 deletion positive. Therefore, with respect to future clinical applications of DCOG ALL9-related treatment protocols, the inclusion of IKZF1 deletion status in risk stratification would further improve the outcome of the largest and mildly treated NHR group, although HR patients are more efficiently recognized. Together, these findings illustrate the prognostic power of IKZF1 deletion mapping in future risk stratifications at diagnosis and may enable a refined stratification of treatment subgroups in ALL9-like protocols. Table 8 ).
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